Results 81 to 90 of about 14,098 (242)
Abstract Despite advancements in epilepsy care, a substantial diagnostic gap persists, particularly in resource‐limited settings. This narrative review explores the potential of video‐based diagnostics augmented by artificial intelligence (AI) to address this gap by enabling earlier and more accessible seizure detection and classification.
Gadi Miron +7 more
wiley +1 more source
Abstract Divergent thinking (DT) is an important constituent of creativity that captures aspects of fluency and originality. The literature lacks multivariate studies that report relationships between DT and its aspects with relevant covariates, such as cognitive abilities, personality traits (e.g. openness), and insight. In two multivariate studies (N
S. Weiss +6 more
wiley +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source
Sudden unexpected death in epilepsy (SUDEP): Risk management of pediatric patients with epilepsy
Abstract Objective Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in people with epilepsy with an incidence of 1:1000. The primary risk factors for SUDEP are generalized or focal to bilateral tonic–clonic seizures. Preventive measures like nighttime monitoring devices and resuscitation training address modifiable risk factors.
Laura Lutz +3 more
wiley +1 more source
When Rare Is Not Small: Amyotrophic Lateral Sclerosis Initiatives and Therapy
In the precision‐medicine era, rare diseases must not be sidelined in translational infrastructure. The Mr. Cai Lei—led “Ice‐Breaking Team” turns an amyotrophic lateral sclerosis patient community into a sustainable ecosystem, realigning philanthropy, data, and research and development to reshape rare‐disease pipelines and guide precision therapies ...
Yang Liu +6 more
wiley +1 more source
The Political Economy of Digital Health Equity: Structural Analysis
Digital technologies have produced many innovations in care delivery and enabled continuity of care for many people when in-person care was impossible. However, a growing body of research suggests that digital health can also exacerbate health
James Shaw, Wiljeana Glover
doaj +1 more source
Characteristics, Motivators, and Enablers of Educators Who Earn Many Micro‐Credentials
ABSTRACT This study explores the characteristics, motivators, and enablers of US educators, who earned more than ten micro‐credentials. Although research exists on attitudes and motivators associated with educators newly engaging with micro‐credentials, it lacks insights into learners earning many micro‐credentials.
Marilys Galindo +1 more
wiley +1 more source
ABSTRACT In France, the Couverture Maladie Universelle Complémentaire (CMU‐C) scheme is a means‐tested, state‐financed, complementary health insurance program that fully covers healthcare. Using administrative claims data and a staggered difference‐in‐differences approach, we estimate the impact of enrollment in the program on healthcare utilization ...
Benoît Carré +2 more
wiley +1 more source
Indicators to identify cancer screening providers with suboptimal case detection: A scoping review
What's New? Quality control of cancer screening programs is essential to maintaining high public health standards. Here, the authors reviewed monitoring of case detection in cervical and colorectal cancer screening programs in Europe, and evaluated its effectiveness. They analysed 20 different measures used for this purpose and showed that many of them
Jiayao Lei +5 more
wiley +1 more source
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel +21 more
wiley +1 more source

